Literature DB >> 16980656

The glucocorticoid receptor N363S polymorphism and steroid response in Duchenne dystrophy.

D M Bonifati1, S F Witchel, M Ermani, E P Hoffman, C Angelini, E Pegoraro.   

Abstract

BACKGROUND: Steroid administration is beneficial in Duchenne muscular dystrophy (DMD), but the response, incidence, and the severity of side effects are variable. AIMS: To investigate whether glucocorticoid receptor (GRL) gene polymorphisms may be responsible for glucocorticoid sensitivity in DMD.
METHODS: Forty eight DMD patients treated either with prednisone or deflazacort were subjected to genetic analyses of the GRL gene.
RESULTS: Mutation studies revealed an heterozygous A to G mutation at GRL cDNA position 1220 in three DMD patients resulting in an asparagine to serine amino acid change at amino acid position 363 (N363S). The N363S carrier DMD patients showed a trend towards a later age at loss of ambulation in comparison with non-carrier patients.
CONCLUSIONS: These data suggest that the N363S GRL polymorphism may be implicated in the long term response to glucocorticoids.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16980656      PMCID: PMC2077532          DOI: 10.1136/jnnp.2005.078345

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN: 0022-3050            Impact factor:   10.154


  21 in total

1.  Report on the 124th ENMC International Workshop. Treatment of Duchenne muscular dystrophy; defining the gold standards of management in the use of corticosteroids. 2-4 April 2004, Naarden, The Netherlands.

Authors:  K Bushby; F Muntoni; A Urtizberea; R Hughes; R Griggs
Journal:  Neuromuscul Disord       Date:  2004-09       Impact factor: 4.296

2.  A comparison of daily and alternate-day prednisone therapy in the treatment of Duchenne muscular dystrophy.

Authors:  G M Fenichel; J R Mendell; R T Moxley; R C Griggs; M H Brooke; J P Miller; A Pestronk; J Robison; W King; L Signore
Journal:  Arch Neurol       Date:  1991-06

Review 3.  Gene regulation by steroid hormones.

Authors:  M Beato
Journal:  Cell       Date:  1989-02-10       Impact factor: 41.582

4.  Clinical investigation of Duchenne muscular dystrophy. Interesting results in a trial of prednisone.

Authors:  M H Brooke; G M Fenichel; R C Griggs; J R Mendell; R T Moxley; J P Miller; K K Kaiser; J M Florence; S Pandya; L Signore
Journal:  Arch Neurol       Date:  1987-08

5.  Prednisone in Duchenne muscular dystrophy.

Authors:  D B Drachman; K V Toyka; E Myer
Journal:  Lancet       Date:  1974-12-14       Impact factor: 79.321

6.  Prednisone in Duchenne dystrophy. A randomized, controlled trial defining the time course and dose response. Clinical Investigation of Duchenne Dystrophy Group.

Authors:  R C Griggs; R T Moxley; J R Mendell; G M Fenichel; M H Brooke; A Pestronk; J P Miller
Journal:  Arch Neurol       Date:  1991-04

7.  Loss of strength and functional decline in Duchenne's dystrophy.

Authors:  K G Allsop; F A Ziter
Journal:  Arch Neurol       Date:  1981-07

8.  Prednisone treatment in Duchenne muscular dystrophy. Long-term benefit.

Authors:  S DeSilva; D B Drachman; D Mellits; R W Kuncl
Journal:  Arch Neurol       Date:  1987-08

9.  Randomized, double-blind six-month trial of prednisone in Duchenne's muscular dystrophy.

Authors:  J R Mendell; R T Moxley; R C Griggs; M H Brooke; G M Fenichel; J P Miller; W King; L Signore; S Pandya; J Florence
Journal:  N Engl J Med       Date:  1989-06-15       Impact factor: 91.245

10.  A multicenter, double-blind, randomized trial of deflazacort versus prednisone in Duchenne muscular dystrophy.

Authors:  M D Bonifati; G Ruzza; P Bonometto; A Berardinelli; K Gorni; S Orcesi; G Lanzi; C Angelini
Journal:  Muscle Nerve       Date:  2000-09       Impact factor: 3.217

View more
  11 in total

1.  Predicting steroid response in muscle disease.

Authors:  N Nirmalananthan; M G Hanna
Journal:  J Neurol Neurosurg Psychiatry       Date:  2006-10       Impact factor: 10.154

Review 2.  Molecular mechanism of glucocorticoid resistance in inflammatory bowel disease.

Authors:  Sara De Iudicibus; Raffaella Franca; Stefano Martelossi; Alessandro Ventura; Giuliana Decorti
Journal:  World J Gastroenterol       Date:  2011-03-07       Impact factor: 5.742

3.  Quantitative assessment of the T2 relaxation time of the gluteus muscles in children with Duchenne muscular dystrophy: a comparative study before and after steroid treatment.

Authors:  Hee Kyung Kim; Tal Laor; Paul S Horn; Brenda Wong
Journal:  Korean J Radiol       Date:  2010-04-29       Impact factor: 3.500

4.  The glucocorticoid receptor gene polymorphism N363S predisposes to more severe toxic side effects during pediatric acute lymphoblastic leukemia (ALL) therapy.

Authors:  O T Eipel; K Németh; D Török; K Csordás; M Hegyi; A Ponyi; A Ferenczy; D J Erdélyi; M Csóka; G T Kovács
Journal:  Int J Hematol       Date:  2013-01-26       Impact factor: 2.490

Review 5.  Old and new therapeutic developments in steroid treatment in Duchenne muscular dystrophy.

Authors:  Corrado Angelini; Enrico Peterle
Journal:  Acta Myol       Date:  2012-05

6.  Retrospective cohort study comparing the efficacy of prednisolone and deflazacort in children with muscular dystrophy: A 6 years' experience in a South Indian teaching hospital.

Authors:  Harish Petnikota; Vrisha Madhuri; Sangeet Gangadharan; Indira Agarwal; Belavendra Antonisamy
Journal:  Indian J Orthop       Date:  2016-09       Impact factor: 1.251

7.  A Reduction in Selenoprotein S Amplifies the Inflammatory Profile of Fast-Twitch Skeletal Muscle in the mdx Dystrophic Mouse.

Authors:  Craig Robert Wright; Giselle Larissa Allsopp; Alex Bernard Addinsall; Natasha Lee McRae; Sofianos Andrikopoulos; Nicole Stupka
Journal:  Mediators Inflamm       Date:  2017-05-16       Impact factor: 4.711

8.  Tumor Necrosis Factor Receptor SF10A (TNFRSF10A) SNPs Correlate With Corticosteroid Response in Duchenne Muscular Dystrophy.

Authors:  Chiara Passarelli; Rita Selvatici; Alberto Carrieri; Francesca Romana Di Raimo; Maria Sofia Falzarano; Fernanda Fortunato; Rachele Rossi; Volker Straub; Katie Bushby; Mojgan Reza; Irina Zharaieva; Adele D'Amico; Enrico Bertini; Luciano Merlini; Patrizia Sabatelli; Paola Borgiani; Giuseppe Novelli; Sonia Messina; Marika Pane; Eugenio Mercuri; Mireille Claustres; Sylvie Tuffery-Giraud; Annemieke Aartsma-Rus; Pietro Spitali; Peter A C T'Hoen; Hanns Lochmüller; Kristin Strandberg; Cristina Al-Khalili; Ekaterina Kotelnikova; Michael Lebowitz; Elena Schwartz; Francesco Muntoni; Chiara Scapoli; Alessandra Ferlini
Journal:  Front Genet       Date:  2020-07-03       Impact factor: 4.599

9.  Description of a Novel Mechanism Possibly Explaining the Antiproliferative Properties of Glucocorticoids in Duchenne Muscular Dystrophy Fibroblasts Based on Glucocorticoid Receptor GR and NFAT5.

Authors:  Sandrine Herbelet; Boel De Paepe; Jan L De Bleecker
Journal:  Int J Mol Sci       Date:  2020-12-03       Impact factor: 5.923

10.  Case Report: Elevated CPK, an indicator of idiopathic inflammatory myopathy?

Authors:  Hina N Khan; Usman Jilani; Shitij Arora
Journal:  F1000Res       Date:  2016-02-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.